ClinicalTrials.gg
RecruitingNCT05173714Updated Jul 27, 2026

Sit Less, Interact and Move More (SLIMM) 2 Study

A Phase 2 interventional study of SLIMM and Standard Resistance Training in Chronic Kidney Diseases and Obesity, sponsored by Srinvasan Beddhu. Recruiting at 2 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Srinvasan Beddhu · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing semaglutide in Renal Insufficiency, Chronic — 9 open to participants now, 9 under way, 1 of them phase 3. Semaglutide · Renal Insufficiency, Chronic.

Planned enrollment
4th of 14
156 · median 77
Started
2021
with 2 others
Phase 2
2 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
1 of 14
Srinvasan Beddhu

Among the 14 studies testing semaglutide in Renal Insufficiency, Chronic, this one is the 4th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 2, and was the 3rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

9 of the 14 studies testing semaglutide in Renal Insufficiency, Chronic are open now, in 9 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing semaglutide in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

  • Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.
  • In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained.
  • Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2.
  • This NIH funded study is conducted at the University of Utah and Stanford University.
  • The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
03

Conditions studied

  • Chronic Kidney Diseases
  • Obesity
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic Kidney Disease Epidemiology Collaboration () Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
  • Able to perform resistance training
  • Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes
  • History of gastroparesis or paralytic ileus
  • At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
  • Potential to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
  • Previous bariatric surgery
  • Medical condition likely to limit survival to less than 1 year
  • Anticipated start of dialysis or kidney transplantation within 6 months
  • Any factors judged by the investigator or study team to likely limit adherence to interventions
  • Vulnerable populations- pregnant or incarcerated
  • Enrolled in interventional trials using drugs or devices
  • Not able to undergo
  • Recent hospitalizations or major interventional procedures done within the past 60 days
  • Known or suspected to tegaderm
  • Use of any GLP-1 receptor agonist within 30 days prior to screening
  • Presently classified as being in (NYHA) Class IV Heart Failure
  • Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
  • Presence of cancer
  • Current use of mobility aid(s)
  • Living in the same household of a participant already enrolled in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Placebo comparator
    SLIMM + Standard RT + Placebo

    SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo

    Behavioral: SLIMM · Behavioral: Standard Resistance Training · Drug: Placebo

  • Active comparator
    SLIMM + Guided RT + Placebo

    SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo

    Behavioral: SLIMM · Behavioral: Guided Resistance Training · Drug: Placebo

  • Experimental
    SLIMM + Guided RT + Semaglutide

    SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide

    Behavioral: SLIMM · Behavioral: Guided Resistance Training · Drug: Semaglutide

Interventions

  • BehavioralSLIMM

    Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.

  • BehavioralStandard Resistance Training

    Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.

  • BehavioralGuided Resistance Training

    Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.

  • DrugPlacebo

    Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.

  • Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.

06

What researchers measure

Primary outcomes

  1. Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization

    The primary analysis will provide estimates and confidence intervals for the three arms comparisons of changes in sedentary duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups that constitute the co-primary comparisons under the study design

    Time frame: Randomization to 12 Months

Secondary outcomes

  1. Average Change in Steps per Day at Months 8, 10 and 12 from Randomization

    The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in steps per day from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.

    Time frame: Randomization to 12 Months

  2. Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization

    The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in stepping duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.

    Time frame: Randomization to 12 Months

  3. Average Change in Six-Minute Walk at Months 6 and 12 from Randomization

    Changes in six minute walk distance from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  4. Average Change in Body Fat % at Months 6 and 12 from Randomization

    Changes in average body fat percentage as measured by bioimpedance analysis from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

Other outcomes

  1. Average Change in Patient Reported Fatigue at Months 6 and 12 from Randomization

    Changes in patient reported fatigue as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  2. Average Change in Patient Reported Sleep at Months 6 and 12 from Randomization

    Changes in patient reported sleep as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  3. Average Change in Patient Reported Quality of Life at Months 6 and 12 from Randomization

    Changes in patient reported quality of life as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  4. Average Change in Lower Extremity Performance Battery Composite Score (LEP-CS) at Months 6 and 12 from Randomization

    Changes in Lower Extremity Performance Battery Composite Score (LEP-CS) from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  5. Average Change in Circulating Protein Markers of Inflammation at Months 6 and 12 from Randomization

    Changes in circulating protein markers of inflammation from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

  6. Average Change in microRNA (miRNA) Markers of Inflammation at Months 6 and 12 from Randomization

    Changes in microRNA (miRNA) markers of inflammation from randomization (at 3 months) to the average of changes at months 6 and 12

    Time frame: Randomization to 12 Months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 58 non-industry phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 60 months is above that.

Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Dec 30, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05173714
Lead sponsor
Srinvasan Beddhu
Responsible party
Srinvasan Beddhu (Professor, Internal Medicine, University of Utah) — Sponsor-investigator
First posted
Dec 30, 2021
Start date
Dec 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Amara Sarwal, M.D.
Contact
Amara.Sarwal@hsc.utah.edu
801-585-9815
Srinivasan Beddhu, M.D.
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion